Abstract:Purpose/Objective(s)To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia.Materials/MethodsPatients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years.ResultsFrom January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up.ConclusionsIMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline. Purpose/Objective(s)To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia. To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia. Materials/MethodsPatients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years. Patients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years. ResultsFrom January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up. From January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up. ConclusionsIMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline. IMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline.

Clinical And Dosimetric Analyses Of Acute Xerostomia For Hypopharynx And Larynx Carcinoma Treated By Rotational Imrt

Comparison of Quality of Life in Patients with Nasopharyngeal Carcinoma Receiving Conventional External Beam Radiation Therapy Versus Intensity Modulated Radiation Therapy

Impact on xerostomia for patients with nasopharyngeal carcinoma treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.

Effect of dose to parotid ducts on Sticky Saliva and Xerostomia in radiotherapy of head and neck squamous cell carcinoma

IMRT for Head and Neck Cancer: Reducing Xerostomia and Dysphagia.

Superficial Parotid Lobe-Sparing Delineation Approach: A Better Method Of Dose Optimization To Protect The Parotid Gland In Intensity-Modulated Radiotherapy For Nasopharyngeal Carcinoma

Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma

Radiation-Induced Xerostomia in Patients with Head and Neck Cancer Treated with Comprehensive Salivary Gland-Sparing Helical Tomotherapy Technique: Based on a Backpropagation Artificial Neural Network

Oncological Outcome of Patients with Salivary Gland Cancer Treated with Surgery and Postoperative Intensity-Modulated Radiotherapy: a Retrospective Study

Diagnosis, Prevention, and Treatment of Radiotherapy-Induced Xerostomia: A Review

Application of Diffusion Kurtosis Imaging in Evaluating Acute Xerostomia in Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy

Assessment of Risk of Xerostomia After Whole-Brain Radiation Therapy and Association With Parotid Dose

Dosimetry of Submandibular Glands on Xerostomia for Nasopharyngeal Carcinoma

Outcomes of xerostomia-related quality of life for nasopharyngeal carcinoma treated by IMRT: based on the EORTC QLQ-C30 and H&N35 questionnaires

Effects of an integrated supportive program on xerostomia and saliva characteristics in patients with head and neck cancer radiated with a low dose to the major salivary glands: a randomized controlled trial

[A retrospective study on combined modality therapy with or without surgery for advanced hypopharyngeal squamous cell carcinoma: an analysis of 119 cases]

Selective Nodal Irradiation by Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma Aiming to Reduce Dysphagia and Xerostomia

P-61 Comparison of Concurrent Chemoradiotherapy or Radiotherapy Alone after Induction Chemotherapy for Hypopharyngeal Cancer

Short-term efficacy comparison between helical tomotherapy and intensity-modulated radiotherapy in patients with locally advanced nasopharyngeal carcinoma

Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma: Virtual Touch Tissue Quantification of Submandibular Gland

Feasibility and Efficacy of Helical Intensity-Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer in Comparison with Conventionally Fractionated 3D-CRT.